Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EyeLief
- Development stage
- Preclinical
- Lead developer
- Re-Vana Therapeutics
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraocular, Intravitreal, Intracameral, Ophthalmic
01
Overview
EyeLief is a preformed, biodegradable implant developed by Re-Vana Therapeutics for sustained intraocular drug delivery. Composed of a photocrosslinked polymeric matrix, it is designed to be injected into the eye using narrow gauge needles. The implant can achieve high loading and sustained release (6+ months) of both small molecule and biologic drugs. Preclinical studies have demonstrated its safety and tolerability following intravitreal and intracameral administration, with no significant irritation or inflammatory response observed over six months. The technology aims to address various ocular diseases by providing customizable release profiles for different therapeutic needs.
- Brand names
- EyeLiefEyeLief-SD
- Other names
- EyeLief SDEyeLief Super Dense
Beyond the preview
Go deeper on EyeLief.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EyeLief.